Addressing dyslipidemic risk beyond LDL-cholesterol

Despite the success of LDL-lowering drugs in reducing cardiovascular disease (CVD), there remains a large burden of residual disease due in part to persistent dyslipidemia characterized by elevated levels of triglyceride-rich lipoproteins (TRLs) and reduced levels of HDL. This form of dyslipidemia i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tall, Alan R., Thomas, David G., Gonzalez-Cabodevilla, Ainara G., Goldberg, Ira J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Review Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718149/
https://www.ncbi.nlm.nih.gov/pubmed/34981790
http://dx.doi.org/10.1172/JCI148559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718149/
https://www.ncbi.nlm.nih.gov/pubmed/34981790
http://dx.doi.org/10.1172/JCI148559

Ejemplares similares